1.74 Dragonfly Therapeutics Announces All Rights Revert to Dragonfly for DF6002, its Proprietary IL12 Investigational Immunotherapy Program

News


<< back

Dragonfly Therapeutics Announces All Rights Revert to Dragonfly for DF6002, its Proprietary IL12 Investigational Immunotherapy Program
Date: 2023-02-06 [news.yahoo.com]

READ THE FULL NEWS >>
×